Combined therapy with epidermal growth factor receptor tyrosine kinase inhibitors for non–small cell lung cancer

Eiji Iwama, Yoichi Nakanishi, Isamu Okamoto

Research output: Contribution to journalReview articlepeer-review

6 Citations (Scopus)

Abstract

Introduction: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have a pronounced clinical benefit for patients with advanced non–small cell lung cancer (NSCLC) positive for EGFR activating mutations. Such individuals inevitably develop resistance to these drugs, however, new treatment strategies to overcome such resistance are being actively pursued. The clinical benefit of EGFR-TKIs for patients with locally advanced NSCLC remains to be clarified. Areas covered: This review summarizes the recent progress in combination treatment with EGFR-TKIs and either chemotherapy or radiotherapy for patients with NSCLC positive for EGFR activating mutations. Expert commentary: Combination therapy with EGFR-TKIs and various other treatment options are under investigation in clinical studies. Although early studies failed to show a clinical benefit for such combination therapy because of a lack of patient selection, clinical studies with patient selection based on EGFR mutation status have shown promising results. Such combination therapy might eventually replace the current standard treatment for patients with NSCLC positive for EGFR activating mutations.

Original languageEnglish
Pages (from-to)267-276
Number of pages10
JournalExpert Review of Anticancer Therapy
Volume18
Issue number3
DOIs
Publication statusPublished - Mar 4 2018

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Combined therapy with epidermal growth factor receptor tyrosine kinase inhibitors for non–small cell lung cancer'. Together they form a unique fingerprint.

Cite this